Online:
Visits:
Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Valeant Pharmaceuticals Intl Inc’s revenues fall again

Tuesday, February 28, 2017 7:42
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Controversial drugs firm Valeant Pharmaceuticals Intl Inc (NYSE:VRX, TSE:VRX) saw its revenue fall for the third quarter in a row at the end of 2016.

The company, which has shed four-fifths of its market value over the last year after a string of profit warnings and earnings restatements, saw its shares slide 5.2% to US$15.84 in pre-market trading after its fourth quarter results were revealed.

Fourth quarter revenues fell to US$2.40bn from US$2.76bn in the same quarter of last year.

A fall in product sales were largely responsible for the decline, while a 3% fall in prices did not help either.

Adjusted underlying earnings (EBITDA) clocked in at US$1.05bn, down from US$1.37bn in the final quarter of 2015.

Adjusted net income of US$441mln, was down from US$542mln the previous year. Adjusted earnings per share slipped to US$1.26 from US$1.55 the previous year, but were ahead of the US$1.19 the market had been expecting.

“We announced financial results that delivered on expectations and demonstrated our commitment to creating the new Valeant,” said Joseph  Papa, who is not only chairman but also chief executive officer of Valeant.

“We paid all 2017 amortizations and reduced debt by US$519 million in the fourth quarter. We agreed to divest a number of assets, including several skincare brands, our Dendreon business and smaller international interests. The US Food and Drug Administration (FDA) approved our new psoriasis treatment, SILIQ, and we resubmitted our glaucoma treatment, latanoprostene bunod in February 2017,” Papa said.

“We are well poised for a turnaround in 2017; we have a lot to look forward to and are excited about the future,” he claimed.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/173935/valeant-pharmaceuticals-intl-inc-s-revenues-fall-again-173935.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.